The Risk of Esophageal Cancer in Relation to the Treatment and Prevention of Osteoporosis in Women
Observational Model: Cohort, Time Perspective: Retrospective
Percentage of Participants With Exposure to Study Drugs (Case-Cohort Analysis)
To determine the use of study drugs (alendronate, etidronate, ibandronate, risedronate, and raloxifene) among female participants with esophageal cancer (cases) and a comparison subcohort, a case-cohort analysis was performed using women meeting criteria from the General Practice Research Database (GPRD, United Kingdom). Exposure to osteoporosis drugs administered 720 days before cancer onset was determined in cases and compared to contemporaneous assessments in a comparison subcohort matched by year of birth and membership in the GPRD on the case's onset date. Cases were confirmed and case onset dates determined by electronic algorithm (based on electronic medical record data) or by medical record review.
Exposure to study drug at least 720 days before disease onset
Alec Walker, MD, DrPH
World Health Information Science Consultants, LLC
United States: Institutional Review Board